

Review Article

MORTALITY PATTERN AMONG TUBERCULOSIS PATIENTS ON TREATMENT IN NIGERIA: A SYSTEMATIC REVIEW AND META-ANALYSIS¹ Musa B. M., ¹ Bashir H.A., ¹ Uloko A.E., ² Garbati M.A., ³ Bakki B., ⁴ Gumi H.S., ⁵ Yusuf A., ⁶ Bello Manga H¹Department of Medicine, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.²Department of Medicine, University of Maiduguri, Borno State Nigeria,³Department of Medicine, Gombe State University/Federal Teaching Hospital Gombe, Gombe State, Nigeria,⁴North Devon District Hospital, Barnstaple, UK, EX311NR,⁵School of Public Health, Texas A & M University College Station, Texas U.S.A., ⁶Department of Hematology and Blood Transfusion. Barau Dikko Teaching Hospital/Kaduna State Teaching Hospital, Kaduna, Nigeria.**ABSTRACT**

Background: Tuberculosis (TB) has continued to be associated with a substantial number of deaths, even in the era of effective antimicrobials. Nigeria is one of the countries with a high tuberculosis burden and has sub-optimal documentation of TB related deaths. Vital statistics/registration is not robust, and mortality surveys are rarely undertaken. In this study, we aimed to determine a precise estimate of TB related deaths on treatment and the trends in death rate while on TB treatment in Nigeria.

Methods: We searched electronic databases for eligible studies from 1st January 2000 to 31st December 2017. We generated pooled death rate estimates using random-effects models and determined trends using meta-regression.

Results: We identified 546 studies, of which 28 fulfilled the criteria for quantitative analysis. Overall, studies reported on 64,999 individuals. The pooled TB death rate during treatment was 6.6% (95% CI; 5.2-8.1%). There was a non-significant rise in TB related deaths on treatment of 0.2% per year (p-value = 0.454).

Conclusion: We found a low TB related deaths on treatment, death rate and slight temporal rise over the study years. There is a need for continuous vital registration, including TB related death, and mortality survey among TB patients.

NigerJmed 2020: 158-162
© 2020. Nigerian Journal of Medicine

INTRODUCTION

In 2016 the World Health Organization (WHO) estimated Tuberculosis (TB) mortality of 17(16-19)/100,000 population among its 194 member states, with 22 high burden countries making a significant contribution.¹ Nigeria is among these high burden countries with a TB incidence and mortality of 307,000/100,000 and 115,000/100,000, respectively.¹ Mortality data for TB had been obtained from vital registrations (VR) and mortality surveys²; however, VR is not robust, and mortality surveys are infrequently done in many developing countries, including Nigeria.³

Tuberculosis related mortality has been a measure of the efficiency of TB control and, as such, it is a prime focus for policymakers.^{4,5} Although concerted efforts to reduce TB death has been ongoing, it is not without challenges. Curbing death from TB has been limited by low case detection, increasing occurrence of TB drug resistance, economic impediments and limited access to TB care.⁶ Furthermore, in spite of attempts at achieving a fairly representative spread of national TB treatment centres

across Nigeria, TB is still associated with death and disability in addition to the indirect cost incurred in an effort to seek care.⁷

With concerns about the completeness of VR and TB case reporting in Nigeria, it is likely that TB prevalence and mortality are underestimated.^{1,8} To improve the reliability of accessible data on TB mortality, repeated community-based surveys would be required not only to appreciate the burden but also to establish trends. In the interim, a meta-analysis of observational studies in epidemiology (MOOSE) technique could be used to enhance the validity of available data. To address this gap, we conducted a meta-analysis to estimate TB mortality rate and trends in patients initiated on TB treatment in Nigeria.

METHODS**Search strategy**

We searched databases such as (PubMed) EMBASE AJOL, BIOLINE, Google scholar and LILACS for studies reporting death among patients with TB. We searched for literature spanning 1st January 2000 to 31st December 2017. The search strategy combined keywords and medical subject headings (MeSH), using multiple search strategies: We used the search strategy of the free text terms 'death' AND 'tuberculosis' with the 'OR' operator including the evaluated MeSH headings 'tuberculosis' AND 'mortality' and 'Nigeria'. We searched retrieved articles in search of other relevant bibliographies. A manual search was done for pertinent literature in subject-specific speciality journals without online versions. Accessible authors were contacted concerning incomplete data.

Correspondence to:

Prof. Andrew E. Uloko,
Department of Medicine,
Bayero University /Aminu Kano Teaching Hospital,
Kano, Nigeria.
Tel: + (234) 8037037749
E-mail: andyuloko@yahoo.com

Eligibility criteria and study selection

Eligible studies comprised of clinical trials, retrospective and prospective cohort studies, cross-sectional studies, and case-control studies (with a report of mortality data) were assessed. We included studies reporting pulmonary and extrapulmonary TB with no sex or age restriction.

We did not include studies on high-risk populations (those with naturally exaggerated death rate) considering their potential to present exaggerated death frequency. Furthermore, presenting data before the year 2000, those with small sample size (which we defined as sample size less than 100) were excluded. We also excluded studies without primary data, commentaries, literature reviews, studies adjudged to have poor quality based on the NIH criteria,⁹ studies with inappropriate data, and studies with inadequate data.

Data Extraction

Two independent reviewers assessed titles and abstracts. We obtained full-text articles of abstracts with information suggestive of fulfilling the inclusion criteria. We abstracted the following information from the eligible studies; name of first author's; year of publication; study design; study setting, age group of the study population, the study setting; anatomical site of TB infection (pulmonary / extra-pulmonary) method of diagnosis, the order of TB treatment (new or retreatment), number of persons with TB, number of deaths while on TB treatment, TB/HIV death and TB death in HIV negative patients. Data was coded based on the author's name, and year of study. We assessed Multiple Coder agreement based on Cohen's kappa.

Operational definitions:

Tuberculosis (TB) death was defined as individual dying during TB treatment (all-cause mortality). The primary outcome measure was the proportion of TB patients on TB treatment that died of TB within the designated period of study.

Quality of Included studies

Study quality was independently assessed by two authors using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.⁹ We evaluated studies with queries appropriate to their study design. Study qualities were graded as good (G), fair (F) or poor (P) according to the rating of at least 70%, 50%, or lower than 50%, respectively.

Statistical analyses

The primary outcome measure was the proportion of death from TB. We estimated standard error of proportions using a binomial probability distribution. Cumulative and subgroup pooled effect size using a random-effect model with DerSimonian-Laird iteration was determined. A pooled proportion estimate and confidence interval, in accordance with the weighted least square (weighting is given by the reciprocal sum of, between and within-study variances), was generated. Between study and heterogeneity using Cochran's Q test was evaluated. We a priori, defined low, medium and high heterogeneity as a Cochran's Q of 25%, 50%, and 75%, respectively. We explored potential confounders and modelled proportion trends using meta-regression. Publication bias with funnel plot, Begg's rank correlation methods and Egger's weighted regression test were assessed. Analyses using STATA software (version

11) was performed. The significance level for Cochran's test was fixed at 0.05. We did iteration sensitivity analysis to determine the effect of sample size variation on the aggregate proportion of TB death.

RESULTS

Characteristics of included studies

We found 546 citations of which 28 articles satisfied all inclusion criteria and were included in both qualitative and quantitative summary (meta-analysis).¹⁰⁻³⁷ (Figure 1) These comprised of 25 retrospective cohort studies and 3 prospective cohort studies with the characteristics of included studies as shown in Table 1. Compliance with meta-analysis guidelines was assessed using PRISMA and MOOSE checklist.

Quality assessment

Based on the 10 quality domains evaluated, all studies satisfied a minimum of six of the quality criteria. A number of benchmark failed were: sample size justification, insufficient sample size, study power description, or variance and effect estimates not properly documented. All included studies had scores of at least 70%; details of the rating process is presented in Table 2.

Overall prevalence

Accordingly, our meta-analysis obtained an overall pooled TB related deaths on treatment prevalence in Nigeria of 6.6% (95% CI; 5.2-8.1%). This was derived from the analysis of cumulative individual data from 64,999 individuals with TB, spanning 17 years (2000-2017). (Figure 2)

Table 1 depicts subgroup analyses for the proportion of TB death based on several characterizations; namely study setting, study design, site of tuberculosis, year of study, age category, site of study, and disease category. Remarkable differences were noted in the proportion of TB related deaths on treatment.

The proportion of death among TB patients was higher in studies within a hospital setting with a prevalence of 4.9% (95% CI: 4.6-5.2) compared to the proportion in the single large community-based study with a prevalence of 0.8% (95% CI: 0.7-0.9).

TB related deaths on treatment was higher in retrospective studies compared to prospective studies, with proportions of 5.8% (95% CI: 5.5-6.1) and 0.8% (95% CI: 0.7-0.9), respectively.

The proportion of death from pulmonary TB was 0.9% (95% CI: 0.8-0.9) compared to 5.9% (95% CI: 5.6-6.2) from both pulmonary and extra-pulmonary sites. When assessed based on year of study, proportions ranged from 0.8% (95% CI: 0.7-0.9) in studies of 2015 to 8.6% (95% CI: 7.5-9.7) in studies of 2003. The pooled proportion in adult populations yielded a higher proportion of TB related deaths on treatment with a figure of 4.3% (95% CI: 4.0-4.7). Conversely, studies restricted to the single site had a higher proportion with a value of 5.4% (95% CI: 5.0-5.7), compared to 1.0% (95% CI: 0.9-1.1) in studies involving multiple sites. Furthermore, studies reporting on new and re-treatment TB cases had a higher pooled proportion of TB related deaths on treatment, with a figure of 4.9% (95% CI: 4.6-5.2)

The proportion TB related deaths on treatment among HIV negative TB patients was 5.2% (95% CI: 3.1-7.3) [Figure 3];

whereas the proportion was 3.6% (95% CI: 2.5-4.7) in those with TB/HIV co-infection. [Figure 4]

We sought evidence of a trend in the proportion of TB related deaths on treatment over the period 2000-2017 using meta-regression modelling.

We found a non-significant rise in the proportion of TB related deaths on treatment among studied Nigerian populations at a rate of 0.2% per year (p-value = 0.454) [Figure 5]. There was no evidence of confounding using covariates: study setting, study design, site of tuberculosis, age category, site of study, and disease category.

We found no evidence of publication bias using Egger's and Begg's test statistics (p-value = 0.101 for both tests). We used augmented data to model data symmetry on the funnel plot. We concluded no graphic evidence of publication bias since augmented plot depicted TB related deaths on treatment in the negative range, which is not biologically plausible. [Figure 6]

DISCUSSION

In this study, we have found a pooled TB death rate of 7% among persons on TB treatment in Nigeria. We have further shown evidence of a non-significant rise in the TB death rate over 17 years. Assuming that Nigeria had a TB incidence of 219/100,000 population in 2016,¹ then we would be estimating an occurrence of TB related deaths on the treatment of 15/100,000 population, with an uncertainty interval of (9-21)/100,000 population. To our knowledge, this study, with an appraisal spanning 2000-2017, is the most robust and extensive review of the burden of TB death in Nigeria so far. Moreover, it is the first study to assess the trend in the TB related deaths on treatment in Nigeria using meta-analysis modelling.

Our finding is consistent with an earlier study by Straetemans et al³⁸, which reported a TB case fatality rate during treatment of 5.8% (95% CI: 3.1%-8.4%) using pooled data from 17 studies with global distribution. Several other Nigerian studies have found low death rate among patients on TB treatment.^{16, 24, 25} Nevertheless, findings from such studies do not consistently depict low TB related deaths on treatment.¹⁵ Our findings suggest a marginal lower TB death rate in HIV positive patients. Although TB could occur at any point along the spectrum of immunoparesis in HIV infection, perhaps our finding could be accounted for by the additive mortality benefit of HIV treatment.^{1,39}

Although there is a decline in global TB related mortality, our data suggest a contrasting rising propensity among treated cases. WHO had reported a similar trend as depicted (graphically) in its 2017 Global TB report.¹

This finding underscores the need for sustained TB surveillance and VR documentation and reportage to serve as a veritable data source for TB control. It equally serves as a mirror of the efficiency of national and global TB control interventions. In the context of global socio-economic dynamics, assessing TB death trend is pertinent because of its critical role in gauging progress towards the "End TB Strategy" milestones of percentage reduction in the absolute number of TB deaths (compared with 2015 baseline) of 35% by 2020, and 75% by 2025.¹

We found a striking difference in higher rates of TB related deaths on treatment in hospital-based studies compared to

report from the community. This could be attributed to the likelihood of patients seen in the hospital being more sick with late presentation.⁴⁰ Similarly, the disparity between retrospective and prospective studies could be due to variation in rigour between the two study designs. Retrospective design is more prone to bias on account of differences in coding and storing mortality data and recall bias.⁴¹ Tuberculosis programs by default rely on microscopic examination of sputum for diagnosis, with microscopy skill acquired over several years having a legacy effect, as such patients presenting with pulmonary TB are more likely to be diagnosed and commenced on therapy early.⁴² It is thus probable that they would have a lower death rate compared to those with extra-pulmonary manifestation. TB related deaths on treatment is higher in children.⁴³ Although we found a lower death rate in children, our finding is insufficient to make such a conclusion. Data from isolated reports are likely to have a smaller study population and accordingly less precise.⁴⁴ Perhaps it may account for the higher death rate reported in single-site studies. Our data suggest higher death occurring among those on re-treatment. Patients on re-treatment for TB are more likely to be non-compliant and defaults on treatment due to treatment fatigue, with an attendant higher risk of dying.⁴⁵ Furthermore, TB/HIV co-infection is associated with an increased risk of death.⁴⁶ A meta-analysis by Jenkins et al. had depicted a higher risk of death in children with TB/HIV co-infection.⁴³ Similarly, an earlier meta-analysis had found a higher risk of TB death when associated with HIV in adults.³⁸ In contrast, we have found a lower rate of death among those with TB/HIV co-infection. Perhaps the difference may be related to active TB case finding among those with HIV and their earlier access to care, as well as the time of commencement of TB therapy. It is worthy of note that only a few studies disaggregated their data by HIV status as such as limiting the power of our deduction. However, further studies would be needed to fully substantiate the assumption.

This study has a number of limitations. There are unrepresented year bands within the study time frame because some studies did not meet the inclusion criteria. It was impossible to compute the proportion of TB death in studies without clearly defined measures of TB cases or with lumped death where we could not delineate death due to TB. We also had to exclude studies solely reporting high-risk populations such as re-treatment or multidrug-resistant tuberculosis (MDR-TB). Including such data would have created a false high death rate. Many societies in Nigeria bury their dead without recourse to documentation with relevant authorities. Thus we are aware of the inherent likelihood of under-reported death in TB occurring outside hospitals. Nevertheless, verbal autopsies still represent the next best source of mortality data, pending when the country would have a robust, vital registration register.

In summation, our meta-analysis has depicted a low overall pooled TB death rate in patients on treatment over two decades, and a non-significant rise in the rate. These findings underpin the need for a concerted effort at consolidating earlier gains made in TB control and establishing mechanisms to eliminate death from TB, culminating in achieving the "End TB Strategy". Indeed,

TB deaths should be preventable with early diagnosis and appropriate treatment.¹ While we were unable to establish HIV treatment status of those with TB/HIV co-infection and timing of commencement of HIV treatment, future studies should aim to include use of anti-retroviral therapy as a potential confounder. This would allow an appreciation of the role of HIV treatment in modulating TB death.

Acknowledgements

We wish to acknowledge the Vanderbilt Institute for Global Health, for Training on Research Ethics. We equally acknowledge the Forgy International Center for funding training in statistic methods in Epidemiology.

Source(s) of support: This study is not supported by any grant.

REFERENCES:

1. WHO | Global tuberculosis report 2017. In: WHO. http://www.who.int/tb/publications/global_report/en/. Accessed 5 Feb 2018
2. Lalor M, Mohiyuddin T, Uddin T, Thomas H, Lipman M, Campbell C. The challenge of estimating TB mortality accurately: reconciling deaths reported in the TB notification system and the vital registration system in England and Wales, 2005–2015 | *Thorax*. http://thorax.bmj.com/content/72/Suppl_3/A84. Accessed 9 Feb 2018
3. Udjo EO (2006) Estimation of mortality from vital registrations in South Africa. *Curr HIV Res* 4:469–474
4. Uplekar M, Weil D, Lonroth K, et al. (2015) WHO's new end TB strategy. *Lancet* 385:1799–1801
5. Raviglione MC (2006) The Global Plan to Stop TB, 2006–2015. *Int J Tuberc Lung Dis* 10:238–239
6. Mhimbira FA, Cuevas LE, Dacombe R, Mkopi A, Sinclair D (2017) Interventions to increase tuberculosis case detection at primary healthcare or community-level services. *Cochrane Database Syst Rev*. DOI: 10.1002/14651858.CD011432.pub2
7. Ukwaja KN, Alobu I, Igwenyi C, Hopewell PC (2013) The High Cost of Free Tuberculosis Services: Patient and Household Costs Associated with Tuberculosis Care in Ebonyi State, Nigeria. *PLoS One*. DOI: 10.1371/journal.pone.0073134
8. Murray CJL, Ortblad KF, Guinovart C, et al. (2014) Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 384:1005–1070
9. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies - NHLBI, NIH. <https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort>. Accessed 28 May 2017
10. Adamu AL, Aliyu MH, Galadanci NA, Musa BM, Gadanya MA, Gajida AU, Amole TG, Bello IW, Gambo S, Abubakar I (2017) Deaths during tuberculosis treatment among paediatric patients in a large tertiary hospital in Nigeria. *PLoS ONE* 12:e0183270.
11. Alobu I, Oshi SN, Oshi DC, Ukwaja KN (2014) Risk factors of treatment default and death among tuberculosis patients in a resource-limited setting. *Asian Pac J Trop Med* 7:977–984
12. Olowe O, Makanjuola O, Adekanmi A, Adefioye O, Olowe R Epidemiological Characteristics and Clinical Outcome of HIV-Related Tuberculosis in a Population of TB Patients in South-western Nigeria. - PubMed - NCBI . <https://www.ncbi.nlm.nih.gov/pubmed/28690879>. Accessed 22 Jan 2018
13. Adegoke OA, Orokotan OA (2013) Evaluation of directly observed treatment short courses at a secondary health institution in Ibadan, Oyo State, Southwestern Nigeria. *Asian Pac J Trop Med* 6:952–959
14. Babatunde OI, Christiandolus EO, Bismarck EC, Emmanuel OI, Chike AC, Gabriel EI (2016) Five years retrospective cohort analysis of treatment outcomes of TB-HIV patients at a PEPFAR/DOTS Centre in South-Eastern Nigeria. *Afr Health Sci* 16:655–662
15. Adamu AL, Gadanya MA, Abubakar IS, Jibo AM, Bello MM, Gajida AU, Babashani MM, Abubakar I (2017) High mortality among tuberculosis patients on treatment in Nigeria: a retrospective cohort study. *BMC Infect Dis* 17:170
16. Jombo GTA, Peters EJ, Gyuse AN, Nwankon JP (2008) Outcome of directly observed therapy short-course (DOTS) regimen in a rural community of the Nigerian Niger Delta. *Niger J Med* 17:61–66
17. Ukwaja KN, Oshi SN, Alobu I, Oshi DC (2016) Profile and determinants of unsuccessful tuberculosis outcome in rural Nigeria: Implications for tuberculosis control. *World J Methodol* 6:118–125
18. Ifebunandu NA, Ukwaja KN, Obi SN (2012) Treatment outcome of HIV-associated tuberculosis in a resource-poor setting. *Trop Doct* 42:74–76
19. Ofoegbu O, Odume B Treatment outcome of tuberculosis patients at National Hospital Abuja Nigeria: a five-year retrospective study: *South Afri Fam Pract: Vol 57, No 1*. <http://www.tandfonline.com/doi/full/10.1080/20786190.2014.995913>. Accessed 9 Feb 2018
20. Ukwaja KN, Oshi SN, Alobu I, Oshi DC (2015) Six- vs eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions. *Int J Tuberc Lung Dis* 19:295–301, i–vii
21. Oshi DC, Oshi SN, Alobu I, Ukwaja KN (2014) Profile and treatment outcomes of tuberculosis in the elderly in southeastern Nigeria, 2011–2012. *PLoS ONE* 9:e111910
22. Adejumo OA, Daniel OJ, Otesanya AF, Salisu-Olatunji SO, Abdur-Razzaq HA (2017) Evaluation of outcomes of tuberculosis management in private for-profit and private-not-for profit directly observed treatment short-course facilities in Lagos State, Nigeria. *Niger Med J* 58:44–49
23. Sunday O, Oladimeji O, Ebenezer F, Akintunde B, Abiola T-O, Saliu A, Abiodun O (2014) Treatment Outcome of Tuberculosis Patients Registered at DOTS Centre in Ogbomoso, Southwestern Nigeria: A 4-Year Retrospective Study. In: *Tubercul Res and Treat*. <https://www.hindawi.com/journals/trt/2014/201705/>. Accessed 22 Jan 2018
24. Obiora Ndubuisi N, Reginald Azu O, Victor Oluoha N, Anthony O (2017) Treatment outcomes of new smear-positive pulmonary tuberculosis patients under directly observed treatment in Anambra state, Nigeria. *Pulm and Crit Care Med*. doi: 10.15761/PCCM.1000128
25. Fatiregun AA, Ojo AS, Bamgboye AE (2009) Treatment outcomes among pulmonary tuberculosis patients at treatment centres in Ibadan, Nigeria. *Ann of Afri Med* 8:100
26. Duru CB, Uwakwe KA, Nnebue CC, Diwe KC, Merenu IA, Emerole CO, Iwu CA, Duru CA (2016) Tuberculosis Treatment Outcomes and Determinants among Patients Treated in Hospitals in Imo State, Nigeria. *Open Access Lib J* 03:1
27. Ukwaja KN, Ifebunandu NA, Osakwe PC, Alobu I (2013) Tuberculosis treatment outcome and its determinants in a tertiary care setting in south-eastern

- Nigeria. Niger Postgrad Med J 20:125–129
28. Musa BM, Gebi U, Falayajo K, Dakum P, Farley J, Blattner W (2009) 255 HIV Related TB: Prospects and Challenges in a High Burden Area, A Case Study of Isoniazid Prophylaxis (IPT) Utilization: JAIDS 51:1
 29. Jamda MA, Lawson L, Nnodu OO, et al. (2014) Treatment outcome of patients co-infected with tuberculosis and HIV in Abuja, Nigeria. Niger J Bas Clin Sci 11:72
 30. Oyefabi Tuberculosis and the determinants of treatment outcome in Zaria, North-Western Nigeria – A nine-year (2007–2015) epidemiological review. (2017). J Med Trop, 19(2):116-122.
 31. Moniruddin C, Faisal M, Alauddin C, Imdadul H An Evaluation of Treatment Outcome in Tuberculosis Directly Observed Treatment Short Course Facilities in Jigawa State, Nigeria (2010–2014) | Jummec: Journal of Health and Translational Medicine (Formerly known as Journal of the University of Malaya Medical Centre). <https://jice.um.edu.my/index.php/jummec/article/view/6681>. Accessed 9 Feb 2018
 32. Ige OM, Akindele MO (2011) Five-year review of treatment outcome of directly observed therapy (DOT) for re-treatment pulmonary tuberculosis patients in UCH, Ibadan, Nigeria. Afr J Med Med Sci 40:15–21
 33. Umo AN, Akpan UP, Afia AA, Utsalo SJ (2005) Pulmonary Tuberculosis: Case Finding and Treatment Outcome at Ekpene Obom (Etinan) Control Center, Nigeria. J Med Lab Sci 14:40–45
 34. Erhabor GE, Adewole O, Adisa AO, Olajolo OA (2003) Directly observed short-course therapy for tuberculosis--a preliminary report of a three-year experience in a teaching hospital. J Natl Med Assoc 95:1082–1088
 35. Salami AK, Oluboyo PO (2003) Management outcome of pulmonary tuberculosis: a nine-year review in Ilorin. West Afr J Med 22:114–119
 36. Ige OM, Oladokun RE (2011) Treatment outcome of newly diagnosed sputum positive adult tuberculosis cases in the context of HIV infection. JIDI 3:210–217
 37. John S, Gidado M, Dahiru T, Fanning A, Codlin AJ, Creswell J (2015) Tuberculosis among nomads in Adamawa, Nigeria: outcomes from two years of active case finding. Int J Tuberc Lung Dis 19:463–468
 38. Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ (2011) Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS ONE 6:e20755
 39. Dheda K, Lampe FC, Johnson MA, Lipman MC (2004) Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 190:1670–1676
 40. Community-Based Active Tuberculosis Case Finding in Poor Urban Settlements of Phnom Penh, Cambodia: A Feasible and Effective Strategy. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092754>. Accessed 11 Feb 2018
 41. Retrospective cohort studies: advantages and disadvantages | The BMJ. <http://www.bmj.com/content/348/bmj.g1072>. Accessed 11 Feb 2018
 42. Chaisson RE, Martinson NA (2008) Tuberculosis in Africa--combating an HIV-driven crisis. N Engl J Med 358:1089–1092
 43. Jenkins HE, Yuen CM, Rodriguez CA, Nathavitharana RR, McLaughlin MM, Donald P, et al. (2017) Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 17:285–295
 44. Some basic aspects of statistical methods and sample size determination in health science research. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279315/>. Accessed 11 Feb 2018
 45. Takarinda KC, Sandy C, Masuka N (2017) Factors Associated with Mortality among Patients on TB Treatment in the Southern Region of Zimbabwe, 2013. In: Tuberc Res Treat. <https://www.hindawi.com/journals/trt/2017/6232071/>. Accessed 11 Feb 2018
 46. Kantipong P, Murakami K, Moolphate S, Aung MN, Yamada N (2012) Causes of mortality among tuberculosis and HIV co-infected patients in Chiang Rai, Northern Thailand. HIV/AIDS (Auckland, NZ) 4:159